Bovine apolipoprotein (apo)A-I displays more enhanced antioxidant and anti-atherosclerotic activity in lipid-free and lipid-bound states than human and porcine apoA-I

Kim,Seong-Min; Park,Ga-Young; Choi,Inho; Cho,Kyung-Hyun

doi:10.3892/ijmm.2013.1473

Bovine apolipoprotein (apo)A-I displays more enhanced antioxidant and anti-atherosclerotic activity in lipid-free and lipid-bound states than human and porcine apoA-I

Authors:
- Seong-Min Kim
- Ga-Young Park
- Inho Choi
- Kyung-Hyun Cho
View Affiliations

Affiliations: School of Biotechnology, Yeungnam University, Gyeongsan, Gyeongbuk 712-749, Republic of Korea
Published online on: August 22, 2013 https://doi.org/10.3892/ijmm.2013.1473
Pages: 843-850

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Apolipoprotein A-I (apoA-I) is a major component of high-density lipoprotein (HDL), which displays anti-atherosclerotic activity in plasma. In the current study, we compared the functional and structural characteristics of human, bovine and porcine apoA-I as regards their antioxidant ability and protein stability. In the lipid-free state, the immunoreactivity of bovine and porcine apoA-I differed from that of human apoA-I and bovine and porcine apoA-I exhibited greater resistance to denaturation induced by urea treatment. Bovine apoA-I showed the weakest binding ability of dimyristoyl phosphatidylcholine; however, bovine apoA-I formed slightly larger reconstituted HDL (rHDL) particles with palmitoyl oleoyl phosphatidylcholine, with a higher number of apoA-I-containing particles. Bovine and porcine apoA-I comprised of pentameric structures, whereas human apoA-I in the rHDL state consisted of trimeric structures. Although apoA-I from all three species showed a similar content of α-helicity in the lipid-free state (approximately 53%), bovine apoA-I showed a lower α-helicity content (approximately 66%) compared with human apoA-I (approximately 74%) in the rHDL state. Bovine apoA-I was more resistant to denaturation and glycation upon treatment with urea and fructose, respectively. Furthermore, bovine apoA-I showed a greater inhibition of cupric ion-mediated low-density lipoprotein (LDL) oxidation and uptake of acetylated LDL by macrophages compared with human or porcine apoA-I in the lipid-free and lipid-bound states. In conclusion, bovine apoA-I has unique functional properties in the lipid-free and lipid-bound states, and displays significantly enhanced anti-atherosclerotic activity.

View Figures

View References

1	Frank PG and Marcel YL: Apolipoprotein A-I: Structure-function relationships. J Lipid Res. 41:853–872. 2000.PubMed/NCBI
2	Fielding PE and Fielding CJ: Plasma membrane caveolae mediate the efflux of cellular free cholesterol. Biochemistry. 34:14288–14292. 1995. View Article : Google Scholar : PubMed/NCBI
3	Rye KA and Barter PJ: Antiinflammatory actions of HDL: a new insight. Arterioscler Thromb Vasc Biol. 28:1890–1891. 2008. View Article : Google Scholar : PubMed/NCBI
4	Kelesidis T, Yang OO, Currier JS, Navab K, Fogelman AM and Navab M: HIV-1 infected patients with suppressed plasma viremia on treatment have pro-inflammatory HDL. Lipids Health Dis. 10:352011. View Article : Google Scholar : PubMed/NCBI
5	Fryirs MA, Barter PJ, Appavoo M, Tuch BE, Tabet F, Heather AK and Rye KA: Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion. Arterioscler Thromb Vasc Biol. 30:1642–1648. 2010. View Article : Google Scholar : PubMed/NCBI
6	Park KH, Yun CO, Kwon OJ, Kim CH, Kim JR and Cho KH: Enhanced delivery of adenovirus, using proteoliposomes containing wildtype or V156K apolipoprotein A-I and dimyristoylphosphatidylcholine. Hum Gene Ther. 21:579–587. 2010. View Article : Google Scholar : PubMed/NCBI
7	Seo J, Yun CO, Kwon OJ, Choi EJ, Song JY, Choi I and Cho KH: A Proteoliposome containing apolipoprotein A-I mutant (V156K) enhances rapid tumor regression activity of human origin oncolytic adenovirus in tumor-bearing zebrafish and mice. Mol Cells. 34:143–148. 2012. View Article : Google Scholar
8	Huang R, Silva RA, Jerome WG, Kontush A, Chapman MJ, Curtiss LK, Hodges TJ and Davidson WS: Apolipoprotein A-I structural organization in high-density lipoproteins isolated from human plasma. Nat Struct Mol Biol. 18:416–422. 2011. View Article : Google Scholar : PubMed/NCBI
9	Bashtovyy D, Jones MK, Anantharamaiah GM and Segrest JP: Sequence conservation of apolipoprotein A-I affords novel insights into HDL structure-function. J Lipid Res. 52:435–450. 2011. View Article : Google Scholar : PubMed/NCBI
10	Brouillette CG, Anantharamaiah GM, Engler JA and Borhani DW: Structural models of human apolipoprotein A-I: a critical analysis and review. Biochim Biophys Acta. 1531:4–46. 2001. View Article : Google Scholar : PubMed/NCBI
11	Brewer HB Jr, Ronan R, Meng M and Bishop C: Isolation and characterization of apolipoproteins A-I, A-II, and A-IV. Methods Enzymol. 128:223–246. 1986. View Article : Google Scholar : PubMed/NCBI
12	Pownall HJ, Massey JB, Kusserow SK and Gotto AM Jr: Kinetics of lipid-protein interactions: interaction of apolipoprotein A-I from human plasma high density lipoproteins with phosphatidylcholines. Biochemistry. 17:1183–1188. 1978. View Article : Google Scholar : PubMed/NCBI
13	Blois MS: Antioxidant determinations by the use of a stable free radical. Nature. 181:1199–1200. 1958. View Article : Google Scholar
14	Cho KH, Park SH, Han JM, Kim HC, Chung YJ, Choi I and Kim JR: A point mutant of apolipoprotein A-I, V156K, exhibited potent anti-oxidant and anti-atherosclerotic activity in hypercholesterolemic C57BL/6 mice. Exp Mol Med. 39:160–169. 2007. View Article : Google Scholar : PubMed/NCBI
15	Cho KH: Synthesis of reconstituted high density lipoprotein (rHDL) containing apoA-I and apoC-III: the functional role of apoC-III in rHDL. Mol Cells. 27:291–297. 2009. View Article : Google Scholar : PubMed/NCBI
16	Staros JV: Membrane-impermeant, cleavable cross-linkers: new probes of nearest neighbor relationships at one face of a membrane. Biophys J. 37:21–22. 1982. View Article : Google Scholar : PubMed/NCBI
17	Chen YH, Yang JT and Martinez HM: Determination of the secondary structures of proteins by circular dichroism and optical rotatory dispersion. Biochemistry. 11:4120–4131. 1972. View Article : Google Scholar : PubMed/NCBI
18	Park KH, Jang W, Kim KY, Kim JR and Cho KH: Fructated apolipoprotein A-I showed severe structural modification and loss of beneficial functions in lipid-free and lipid-bound state with acceleration of atherosclerosis and senescence. Biochem Biophys Res Commun. 392:295–300. 2010. View Article : Google Scholar
19	Markwell MA, Haas SM, Bieber LL and Tolbert NE: A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem. 87:206–210. 1978. View Article : Google Scholar : PubMed/NCBI
20	Esterbauer H, Striegl G, Puhl H and Rotheneder M: Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun. 6:67–75. 1989. View Article : Google Scholar : PubMed/NCBI
21	Noble RP: Electrophoretic separation of plasma lipoproteins in agarose gel. J Lipid Res. 9:693–700. 1968.PubMed/NCBI
22	Fraenkel-Conrat H: Methods for investigating the essential groups for enzyme activity. Methods Enzymol. 4:247–269. 1957. View Article : Google Scholar
23	Cho KH: Biomedicinal implications of high-density lipoprotein: its composition, structure, functions, and clinical applications. BMB Rep. 42:393–400. 2009. View Article : Google Scholar : PubMed/NCBI
24	Rubin EM, Krauss RM, Spangler EA, Verstuyft JG and Clift SM: Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 353:265–267. 1991. View Article : Google Scholar : PubMed/NCBI
25	Newton RS and Krause BR: HDL therapy for the acute treatment of atherosclerosis. Atheroscler Suppl. 3:31–38. 2002. View Article : Google Scholar : PubMed/NCBI
26	Nicholls SJ, Uno K, Kataoka Y and Nissen SE: ETC-216 for coronary artery disease. Expert Opin Biol Ther. 11:387–394. 2011. View Article : Google Scholar : PubMed/NCBI
27	Collet X, Marcel YL, Tremblay N, Lazure C, Milne RW, Perret B and Weech PK: Evolution of mammalian apolipoprotein A-I and conservation of antigenicity: correlation with primary and secondary structure. J Lipid Res. 38:634–644. 1997.PubMed/NCBI
28	Jonas A and Krajnovich DJ: Effect of cholesterol on the formation of micellar complexes between bovine A-I apolipoprotein and L-alpha-dimyristoylphosphatidylcholine. J Biol Chem. 253:5758–5763. 1978.
29	Oikawa S, Katoh N, Itoh H, Miyamoto T, Konno M and Kajita T: Decreased serum apolipoprotein A-I concentrations in cows infected with Salmonella typhimurium. Can J Vet Res. 61:182–186. 1997.PubMed/NCBI
30	Lee H, Park JE, Choi I and Cho KH: Enhanced functional and structural properties of high-density lipoproteins from runners and wrestlers compared to throwers and lifters. BMB Rep. 42:605–610. 2009. View Article : Google Scholar : PubMed/NCBI